An Assay for the Determination of Sirolimus Levels in the Lymphocyte of Transplant Patients

Transplantation Proceedings

Volumn 39, Issue 4, 2007, Pages 1204-1206

  Masri, M ^a   Rizk, S ^a   Barbari, A ^a   Stephan, A ^a   Kamel, G ^b   Rost, M ^c  

^a TransMedical Research Institute   (Lebanon)

^b Lebanese Institute for Renal Disease   (Lebanon)

^c UNIVERSITY OF SOUTH BOHEMIA   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG BIOAVAILABILITY; DRUG DETERMINATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; TRANSPLANTATION;

DRUG MONITORING; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOCYTES; MALE; SIROLIMUS;

EID: 34248559596     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.04.008     Document Type: Article

References (13)

1. Vezina C., Kudelski A., and Sehgal S.N. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of active principle. J Antibiot 28 (1975) 721
2. Sehgal S.N., Baker H., and Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic, II. Fermentation, isolation and characterization. J Antibiot 28 (1975) 727
3. Sehgal S.N. Rapamune (Sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit 17 (1995) 660
4. Sehgal S.N. Rapamune (RAPA, rapamycin, Sirolimus) Mechanism of action immunosuppressive effect results from blockade of ignal transduction and inhibition of cell cycle progression. Clin Biochem 31 (1998) 335
5. Boyel M.J., and Kahan B.D. Immunosuppressive role of rapamycin in allograft rejection. In: Thomson A.W., and Starzl T.E. (Eds). Immunosuppressive drugs: development in anti-rejection therapy (1994), Edward Arnold, London 129
6. Tu Y., Stepkowski S.M., Chou T.C., et al. The synergistic effects of cyclosporine, sirolimus and brequinar on heart allograft survival in mice. Transplantation 59 (1995) 177
7. Barbari A., Masri M.A., Stephan A., et al. Cyclosporine lymphocyte versus whole blood pharmacokinetic monitoring: correlation with histological findings. Transplant Proc 33 (2001) 2782
8. Barbari A., Stephan A., Masri M., et al. Cyclosporine lymphocyte level and lymphocyte count: new guidelines for tailoring immunosuppressive therapy. Transplant Proc 35 (2003) 2742
9. Masri M.A., Barbari A., Stephan A., et al. Measurement of lymphocyte cyclosporine levels in transplant patients. Transplant Proc 30 (1998) 3561
10. Masri M. Bioavailability versus bioequivalence: the cyclosporine model. Exp Clin Transplant 1 (2003) 119
11. Barbari A., Masri M., Stephan A., et al. Cyclosporine lymphocyte maximum level: a new alternative for cyclosporine monitoring in kidney transplantation. Exp Clin Transplant 1 (2005) 293
12. Barbari A., Masri M., Stephan A., et al. Cyclosporine lymphocyte maximum level: in de novo kidney transplant patients: a prospective study. Exp Clin Transplant 1 (2005) 293
13. Stephan A., Masri M.A., Barbari A., et al. Therapeutic drug level monitoring for mycophenolate Mofetil: is it justified?. Transplant Proc 33 (2001) 2778